Opendata, web and dolomites

DRIVE SIGNED

Diabetes Reversing Implants with enhanced Viability and long-term Efficacy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DRIVE project word cloud

Explore the words cloud of the DRIVE project. It provides you a very rough idea of what is the project "DRIVE" about.

ease    retention    create    t2    glycemic    localised    specialised    degradation    demand    vitro    cure    diabetes    382    risk    sensitive    peritoneum    retrievable    resistance    biofunctionalised    disease    transport    injection    tuneable    islet    interactive    cell    vascularisation    vein    sources    housed    pancreatic    microencapsulated    oxygenation    vivo    cath    bio    sufferers    isdm    protective    efficacy    microparticles    stem    beta    models    donor    pluripotent    t1    drug    supply    diabetics    lifelong    t1d    portal    storage    profiles    technologies    systemic    minimally    survival    catheter    invasive    clinical    chronic    laparoscopic    million    cues    macrocapsule    residence    yield    immunoprotection    deposition    therapy    characterised    extremely    added    worldwide    preservation    gel    inadequate    handling    brittle    people    dimensional    harvesting    mellitus    gels    extended    poor    blood    insulin    limit    procedure    omental    injectable    human    safe    release    porous    shell    agents    containing    treatment    immunosuppressive    compatibility    suite    glucose    engraftment    transplantation    experts    islets    time    polymeric    fold    hydrogels    drive    cells   

Project "DRIVE" data sheet

The following table provides information about the project.

Coordinator
NATIONAL UNIVERSITY OF IRELAND GALWAY 

Organization address
address: UNIVERSITY ROAD
city: Galway
postcode: H91
website: www.nuigalway.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.drive-project.eu
 Total cost 8˙832˙062 €
 EC max contribution 8˙832˙061 € (100%)
 Programme 1. H2020-EU.2.1.3.1. (Cross-cutting and enabling materials technologies)
 Code Call H2020-NMP-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) coordinator 435˙576.00
2    ABIEL SOCIETA A RESPONSABILITA LIMITATA IT (PALERMO) participant 887˙366.00
3    EXPLORA SRL IT (ROMA) participant 820˙000.00
4    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) participant 812˙141.00
5    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 715˙020.00
6    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 700˙496.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 679˙153.00
8    INNOCORE TECHNOLOGIES BV NL (Groningen) participant 600˙812.00
9    CONTIPRO AS CZ (DOLNI DOBROUC) participant 600˙625.00
10    DUBLIN CITY UNIVERSITY IE (DUBLIN) participant 600˙000.00
11    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 579˙113.00
12    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 550˙452.00
13    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 498˙555.00
14    INNOVA SRL IT (ROMA) participant 273˙000.00
15    L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA IT (MILANO) participant 79˙750.00
16    AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA IT (MILANO) participant 0.00

Map

 Project objective

Diabetes mellitus is a chronic disease characterised by high blood glucose due to inadequate insulin production and/or insulin resistance which affects 382 million people worldwide. Pancreatic islet transplantation is an extremely promising cure for insulin-sensitive diabetes mellitus (ISDM), but side effects of lifelong systemic immunosuppressive therapy, short supply of donor islets and their poor survival and efficacy in the portal vein limit the application of the current clinical procedure to the most at-risk brittle Type I diabetes (T1D) sufferers. The DRIVE consortium will develop a novel suite of bio-interactive hydrogels (β-Gel) and on-demand drug release systems to deliver islets in a protective macrocapsule (β-Shell) to the peritoneum with targeted deposition using a specialised injection catheter (β-Cath). Pancreatic islets will be microencapsulated in β-Gels; biofunctionalised injectable hydrogels containing immunosuppressive agents and polymeric microparticles with tuneable degradation profiles for localised delivery of efficacy cues. These β-Gels will be housed in a porous retrievable macrocapsule, β-Shell, for added retention, engraftment, oxygenation, vascularisation and immunoprotection of the islets. A minimally invasive laparoscopic procedure (O-Fold) will be used to create an omental fold and at the same time deliver β-Shell. An extended residence time in β-Gel will enhance long-term clinical efficacy of the islets and result in improved glycemic control. The novel β-Gels will also be developed as human three-dimensional in-vitro models of in-vivo behaviour. Islet harvesting and preservation technologies will be developed to facilitate their optimised yield, safe handling and transport, and ease of storage. DRIVE will also enable the future treatment of a broader range of T1 and insulin-sensitive T2 diabetics by working with induced pluripotent stem cell experts to ensure the compatibility of our system with future stem cell sources of β-cells.

 Deliverables

List of deliverables.
Dissemination and Data Management Plan (DMP) and introductory project dissemination material Documents, reports 2019-10-08 17:13:00
Outcomes of patients and citizens panel’s report Documents, reports 2019-10-08 17:12:44
Project website Websites, patent fillings, videos etc. 2019-10-08 17:12:40
Report on patient advocacy activities Documents, reports 2019-10-08 17:13:00

Take a look to the deliverables list in detail:  detailed list of DRIVE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Aline Zbinden, Julia Marzi, Katharina Schlünder, Christopher Probst, Max Urbanczyk, Scott Black, Eva M. Brauchle, Shannon L. Layland, Udo Kraushaar, Garry Duffy, Katja Schenke-Layland, Peter Loskill
Non-invasive marker-independent high content analysis of a microphysiological human pancreas-on-a-chip model
published pages: , ISSN: 0945-053X, DOI: 10.1016/j.matbio.2019.06.008
Matrix Biology 2019-08-30
2018 Federico Bertuzzi, Luciano De Carlis, Mario Marazzi, Antonio Gaetano Rampoldi, Matteo Bonomo, Barbara Antonioli, Marta Cecilia Tosca, Marta Galuzzi, Andrea Lauterio, Danila Fava, Patrizia Dorighet, Andrea De Gasperi, Giacomo Colussi
Long-term Effect of Islet Transplantation on Glycemic Variability
published pages: 840-846, ISSN: 0963-6897, DOI: 10.1177/0963689718763751
Cell Transplantation 27/5 2019-08-30
2017 Alan J .Ryan, Hugh S O’Neill, Garry P Duffy, Fergal J O’Brien
Advances in polymeric islet cell encapsulation technologies to limit the foreign body response and provide immunoisolation
published pages: 66-71, ISSN: 1471-4892, DOI: 10.1016/j.coph.2017.07.013
Current Opinion in Pharmacology 36 2019-08-30
2018 Albert Espona-Noguera, Jesús Ciriza, Alberto Cañibano-Hernández, Luis Fernandez, Ignacio Ochoa, Laura Saenz del Burgo, Jose Luis Pedraz
Tunable injectable alginate-based hydrogel for cell therapy in Type 1 Diabetes Mellitus
published pages: 1261-1269, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2017.09.103
International Journal of Biological Macromolecules 107 2019-08-30
2017 S. Acreman, H. Brandhorst, A. Abraham, P.R.V. Johnson, D. Brandhorst
Effect of Etanercept Concentration on Human Islet Integrity
published pages: 2327-2329, ISSN: 0041-1345, DOI: 10.1016/j.transproceed.2017.11.002
Transplantation Proceedings 49/10 2019-08-30
2018 Bertuzzi F, Colussi G, Lauterio A, De Carlis L.
Intramuscular islet allotransplantation in type 1 diabetes mellitus.
published pages: , ISSN: 1128-3602, DOI: 10.26355/eurrev_201803_14588
Eur Rev Med Pharmacol Sci 2019-08-30
2019 Karina C. Scheiner, Roel F. Maas-Bakker, Thanh T. Nguyen, Ana M. Duarte, Gert Hendriks, Lídia Sequeira, Garry P. Duffy, Rob Steendam, Wim E. Hennink, Robbert J. Kok
Sustained Release of Vascular Endothelial Growth Factor from Poly(ε-caprolactone-PEG-ε-caprolactone)- b -Poly( l -lactide) Multiblock Copolymer Microspheres
published pages: 11481-11492, ISSN: 2470-1343, DOI: 10.1021/acsomega.9b01272
ACS Omega 4/7 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.1.)

MOSTOPHOS (2015)

Modelling stability of organic phosphorescent light-emitting diodes

Read More  

ELASTISLET (2015)

Tailored Elastin-like Recombinamers as Advanced Systems for Cell Therapies in Diabetes Mellitus: a Synthetic Biology Approach towards a Bioeffective and Immunoisolated Biosimilar Islet/Cell Niche

Read More  

EXTMOS (2015)

EXTended Model of Organic Semiconductors

Read More